1. White MF. Longevity. Mapping the path to a longer
life. Nature 524:170-171, 2015.
2. Levine R, Goldstein M, Klein S and Huddelston B. 1949.
The action of insulin on the distribution of galactose in eviscerated and
nephrectomized dogs. J Biol Chem 179:985-986.
3. De Meyts P. 2004. Insulin and its receptor: structure,
function and evolution. BioEssays 26:1351-1362.
4. Petruzzelli LM, Ganguly S, Smith CJ, Cobb MH, Rubin CS
and Rosen OM. 1982. Insulin activates a tyrosine-specific protein kinase in
extracts of 3T3-L1 adipocytes and human placenta. Proc Natl Acad Sci USA
79:6792-6796.
5. Ebina Y, Ellis L, Jamagin K, Edery M, Graf L, Clauser
E, Ou J-H, Masiarz F, Kan YW, Goldfine ID, Roth RA and Rutter WJ. 1985. The
human insulin receptor cDNA: the structural basis for hormone-activated
transmembrane signalling. Cell 40:747-758.
6. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzelli LM,
Dull TJ, Gray A, Coussens L, Liao YC, Tsubokawa M, Mason A, Seeburg PH,
Grunfeld C, Rosen M and Ramachandran J. 1985.Human insulin receptor and its
relationship to the tyrosine kinase family of oncogenes. Nature 313:765-761.
7. De Meyts P. 2016. The Insulin Receptor and Its Signal
Transduction Network. De Groot LJ, Chrousos G, Dungan K, et al., editors. South
Dartmouth (MA): MDText.com, Inc.; 2000-.
8. De Meyts P and Whittaker J. 2002 Structural biology of
insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Disc 1:
769-783.
9. Sparrow LG, McKern NM, Gorman JJ, Strike PM, Robinson
CP, Bentley JD, Ward CW. 1997. The disulfide bonds in the C-terminal domains of
the human insulin receptor ectodomain. J Biol Chem 272: 29460–29467.
10. Hubbard SR. 2013. The insulin receptor: both a
prototypical and atypical receptor tyrosine kinase. Cold Spring Harb Perspect
Biol. 1; 5 (3) 2013.
11. Smith BJ, Huang K, Kong G, Chan SJ, Nakagawa S,
Menting JG, Hu SQ, Whittaker J, Steiner DF, Katsoyannis PG, Warda CW, Weissb
MA, and Lawrenceal MC. 2010. Structural
resolution of a tandem hormone-binding element in the insulin receptor and its
implications for design of peptide agonists. Proc Natl Acad Sci 107: 6771–6776.
12. Whittaker L, Hao C, Fu W, Whittaker J. 2008.
High-affinity insulin binding: Insulin interacts with two receptor ligand
binding sites. Biochemistry 47: 12900–12909.
13. Hubbard SR. 1997. Crystal structure of the activated
insulin receptor tyrosine kinase in complex with peptide substrate and ATP
analog. EMBO J 16: 5572–5581.
14. De Meyts P. 2008. The insulin receptor: A prototype
for dimeric, allosteric membrane receptors? Trends Biochem Sci 33: 376–384.
15. Ward CW and Lawrence MC. 2012. Similar but different:
Ligand-induced activation of the insulin and epidermal growth factor receptor
families. Curr Opin Struct Biol 22: 360–366.
16. Li S, Covino ND, Stein EG, Till JH, Hubbard SR. 2003.
Structural and biochemical evidence for an autoinhibitory role for tyrosine 984
in the juxtamembrane region of the insulin receptor. J Biol Chem 278:
26007–26014.
17. Hubbard SR, Wei L, Ellis L, Hendrickson WA. 1994.
Crystal structure of the tyrosine kinase domain of the human insulin receptor.
Nature 372: 746–754.
18. Wei L, Hubbard SR, Hendrickson WA, Ellis L. 1995.
Expression, characterization, and crystallization of the catalytic core of the
human insulin receptor protein-tyrosine kinase domain. J Biol Chem 270:
8122–8130.
19. Wu J, Li W, Craddock BP, Foreman KW, Mulvihill MJ, Ji
QS, Miller WT, Hubbard SR. 2008. Small-molecule inhibition and activation-loop
trans-phosphorylation of the IGF1 receptor. EMBO J 27: 1985–1994.
20. Taniguchi CM, Emanuelli B and Kahn CR. 2006. Critical
nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell
Biol 7: 85-96.
21. Versteyhe S, Blanquart C, Hampe C, Mahmood S,
Christoff N, De Meyts P, Gray SG and Issad T. 2010. IRS-5 and -6 are poor
substrates for the insulin receptor. Mol Med Rep 3:189-193.
22. Cantley LC. 2002. The phosphoinositide 3-kinase
pathway. Science 296:1655-1657.
23. Avruch J. 2007. MAP kinase pathways: the first twenty
years. Biochim Biophys Acta 1773:1150-1160.
24. Harris TE and Lawrence JC Jr. 2003. TOR signaling.
Sci. STKE 2003, RE 15.
25. Cohen P. 2001. The renaissance of GSK3. Nat Rev Mol
Cell Biol 2:767-776.
26. Accili D and Arden KC. 2004. FoxOs at the crossroads
of cellular metabolism, differentiation and transformation. Cell117:421-426.
27. Svendsen AM, Winge SB, Zimmermann M, Lindvig AB,
Warzecha CB, Sajid W, Horne MC and De Meyts P, 2014. Downregulation of cyclin
G2 by insulin, IGF-I (insulin-like growth factor 1) and X10 (Asp B10
insulin):role in mitogenesis. Biochem J 457:69-77.
28. Sano H, Kane S, Sano E, Miiner CP, Asara JM, Lane WS,
Garner CW and Lienhard GE. 2003. Insulin-stimulated phosphorylation of Rab
GTPase-activating protein regulates GLUT4 translocation. J Biol Chem
278:14599-14602.
29. Yu Q, Gao F and Ma XL 2011. Insulin says NO to
cardiovascular disease. Cardiovasc Res 89: 516–524
30. Thong FSL, Dugani CB and Klip A. 2005. Turning Signals
On and Off: GLUT4 Traffic in the Insulin-Signaling Highway. Physiology 20:
271-284.
31. Huang S and Czech MP. . 2007. The GLUT4 glucose
transporter. Cell Metab 5:237-252
32. Satoh S, Nishimura H, Clark AE, Kozka IJ, Vannucci SJ,
Simpson IA, Quon MJ, Cushman SW, and Holman GD. 1993. Use of bismannose
photolabel to elucidate insulin-regulated GLUT4 subcellular trafficking
kinetics in rat adipose cells. Evidence that exocytosis is a critical site of
hormone action. J Biol Chem 268: 17820–17829.
33. Eguez L, Lee A, Chavez JA, Miinea CP, Kane S, Lienhard
GE, and McGraw, TE. 2005. Full intracellular retention of GLUT4 requires AS160
Rab GTPase activating protein. Cell Metab; 2: 263–272
34. Farese R. V. 2002. Function and dysfunction of aPKC
isoforms for glucose transport in insulin-sensitive and insulin resistant
states. Am. J. Physiol. Endocrinol. Metab. 283, E1–E11.
35. Farese R V. Sajan MP. and Standaert ML. 2005. Atypical protein kinase C in insulin action
and insulin resistance. Biochem. Soc. Trans. 33, 350–353.
36. Chiang SH, Baumann CA, Kanzaki M, Thurmond DC, Watson
RT, Neudauer CL, Macara IG, Pessin JE, and Saltiel AR. 2001. Insulin-stimulated
GLUT4 translocation requires the CAP-dependent activation of TC10. Nature 410:
944–948.
37. Tong P, Khayat ZA, Huang C, Patel N, Ueyama A, and
Klip A. 2001. Insulin-induced cortical actin remodeling promotes GLUT4
insertion at muscle cell membrane ruffles. J Clin Invest 108: 371–381.
38. Wang Q, Somwar R, Bilan PJ, Liu Z, Jin J, Woodgett JR,
and Klip A. 1999. Protein kinase B/Akt participates in GLUT4 translocation by
insulin in L6 myotubes. Mol Cell Biol 19: 4008–4018.
39. Kanzaki M and Pessin JE. 2001. Insulin-stimulated
GLUT4 translocation in adipocytes is dependent upon cortical actin remodeling.
J Biol Chem 276: 42436–42444.
40. González-Mujica
F. 2016. Drogas antidiabéticas diferentes de la insulina. Mecanismos de acción.
Vitae. Abril-Junio
Nº 66. Disponible en: http://vitae.ucv.ve/?module=articulo&rv=124&n=5316.
41. Gual P, Marchand-Brustel Y, and Tanti JF. 2005.Positive and negative regulation of
insulin signaling through IRS-1 phosphorylation. Biochimie 87: 99–109.
42. Galic S, Hauser C, Kahn BB, Haj FG, Neel BG, Tonks NK,
and Tiganis T. 2005. Coordinated regulation of insulin signaling by the protein
tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol 25: 819–829.
43. Ugi
S, Imamura T, Maegawa H, Egawa K, Yoshizaki T, Shi K, Obata T, Ebina Y,
Kashiwagi A, and Olefsky JM. 2004. Protein phosphatase 2A negatively regulates insulin’s metabolic
signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1
adipocytes. Mol Cell Biol 24: 8778–8789.
44. Ono H, Katagiri H, Funaki M, Anai M, Inukai K,
Fukushima Y, Sakoda H, Ogihara T, Onishi Y, Fujishiro M, Kikuchi M, Oka Y, and
Asano T. 2001. Regulation of phosphoinositide metabolism, Akt phosphorylation,
and glucose transport by PTEN (phosphatase and tensin homolog deleted on
chromosome 10) in 3T3-L1 adipocytes. Mol Endocrinol 15: 1411–1422.
45. Carpentier JL. 1994. Insulin receptor internalization:
molecular mechanisms and pathophysiological implications. Diabetologia 37 Suppl
2: S117-S124
46. Duckworth WC, Bennett RG and Hamel FG. 1998. Insulin
degradation: progress and potential. Endocr Rev. 19: 608-624.